A Phase I Clinical Study of CWP232291 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome Having Failed Hypomethylating Treatment, and High-Risk Myelofibrosis.

Trial Profile

A Phase I Clinical Study of CWP232291 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome Having Failed Hypomethylating Treatment, and High-Risk Myelofibrosis.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Mar 2016

At a glance

  • Drugs CWP 291 (Primary)
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Myelofibrosis
  • Focus Adverse reactions
  • Sponsors JW Pharmaceutical
  • Most Recent Events

    • 07 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Jun 2015 Recruitment is continuing, as reported at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 Interim results in 56 patients presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top